{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:11:27Z","timestamp":1790957487870,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011828","name":"Guangxi Zhuang Autonomous Region Health and Family Planning Commission","doi-asserted-by":"publisher","award":["Z-B20241417"],"award-info":[{"award-number":["Z-B20241417"]}],"id":[{"id":"10.13039\/501100011828","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Medical Association"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jnma.2025.08.110","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T12:47:13Z","timestamp":1758026833000},"page":"458-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of SGLT2 inhibitors on acute kidney injury in patients with chronic kidney disease, cardiovascular disease, and type 2 diabetes: A meta-analysis"],"prefix":"10.1016","volume":"117","author":[{"given":"Zhiyuan","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8842-7174","authenticated-orcid":false,"given":"Wenqing","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhougui","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jnma.2025.08.110_bib0001","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MAJ.0b013e318068ddf9","article-title":"Risk markers for contrast-induced nephropathy [J]","volume":"334","author":"Toprak","year":"2007","journal-title":"Am J Med Sci"},{"issue":"7","key":"10.1016\/j.jnma.2025.08.110_bib0002","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","article-title":"Post-contrast acute kidney injury \u2013 Part 1: definition, clinical features, incidence, role of contrast medium and risk factors [J]","volume":"28","author":"Van Der Molen","year":"2018","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","article-title":"Renal glucose reabsorption inhibitors to treat diabetes [J]","volume":"32","author":"Bailey","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jnma.2025.08.110_bib0004","doi-asserted-by":"crossref","first-page":"n1091","DOI":"10.1136\/bmj.n1091","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline [J]","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jnma.2025.08.110_bib0005","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use [J]","volume":"18","author":"Van Der Aart-Van Der Beek A","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0006","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA [J]","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol Dialysis Transplant"},{"issue":"17","key":"10.1016\/j.jnma.2025.08.110_bib0007","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus [J]","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jnma.2025.08.110_bib0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pcd.2018.02.001","article-title":"SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis [J]","volume":"12","author":"Seidu","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.jnma.2025.08.110_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [J]","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2021.05.005","article-title":"Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial [J]","volume":"79","author":"Heerspink","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0011","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease [J]","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jnma.2025.08.110_bib0012","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program [J]","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jnma.2025.08.110_bib0013","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function [J]","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jnma.2025.08.110_bib0014","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial [J]","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jnma.2025.08.110_bib0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function insights from EMPEROR-reduced [J]","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jnma.2025.08.110_bib0016","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE Trial [J]","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0017","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study [J]","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jnma.2025.08.110_bib0018","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13920","article-title":"Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program [J]","volume":"22","author":"Ohkuma","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0019","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/ehf2.13236","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program [J]","volume":"8","author":"Yu","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.jnma.2025.08.110_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jdi.13624","volume":"13","author":"Wada","year":"2022","journal-title":"J Diabetes Investig"},{"issue":"22","key":"10.1016\/j.jnma.2025.08.110_bib0021","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes [J]","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.jnma.2025.08.110_bib0022","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J]","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med"},{"issue":"24","key":"10.1016\/j.jnma.2025.08.110_bib0023","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J]","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.jnma.2025.08.110_bib0024","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes [J]","volume":"380","author":"Wiviott","year":"2019","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.jnma.2025.08.110_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial [J]","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.jnma.2025.08.110_bib0026","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s10157-024-02489-4","article-title":"Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY [J]","volume":"28","author":"Nangaku","year":"2024","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"10.1016\/j.jnma.2025.08.110_bib0027","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial [J]","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0028","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease [J]","volume":"384","author":"Bhatt","year":"2021","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.jnma.2025.08.110_bib0029","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.0000000000000414","article-title":"Sotagliflozin and kidney outcomes, kidney function, and albuminuria in type 2 diabetes and CKD: a secondary analysis of the SCORED trial [J]","volume":"19","author":"Sridhar","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.jnma.2025.08.110_bib0030","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1111\/dom.15685","article-title":"Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial [J]","volume":"26","author":"Cardoza","year":"2024","journal-title":"Diabetes Obesity Metabol"},{"issue":"3","key":"10.1016\/j.jnma.2025.08.110_bib0031","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.15380","article-title":"Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: a post hoc analysis of the CANVAS Program [J]","volume":"26","author":"Chen","year":"2024","journal-title":"Diabetes Obesity Metabol"},{"issue":"18","key":"10.1016\/j.jnma.2025.08.110_bib0032","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease insights from the CREDENCE trial [J]","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jnma.2025.08.110_bib0033","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 Study [J]","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jnma.2025.08.110_bib0034","doi-asserted-by":"crossref","unstructured":"Salvatore T, Galiero R, Caturano A, et al. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors [J\/OL] 2022, 23(7):10.3390\/ijms23073651","DOI":"10.3390\/ijms23073651"},{"issue":"10","key":"10.1016\/j.jnma.2025.08.110_bib0035","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure [J]","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jnma.2025.08.110_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101254","article-title":"PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation [J]","volume":"26","author":"Lin","year":"2019","journal-title":"Redox Biol"},{"key":"10.1016\/j.jnma.2025.08.110_bib0037","article-title":"NLRP3 inflammasome mediates contrast media-induced acute kidney injury by regulating cell apoptosis [J]","volume":"6","author":"Shen","year":"2016","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jnma.2025.08.110_bib0038","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41419-018-1023-x","article-title":"Caspase-11-mediated tubular epithelial pyroptosis underlies contrast-induced acute kidney injury [J]","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis"},{"issue":"31","key":"10.1016\/j.jnma.2025.08.110_bib0039","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/eurheartj\/ehad283","article-title":"Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial [J]","volume":"44","author":"Chatur","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jnma.2025.08.110_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028739","article-title":"Effects of dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA-CKD Trial [J]","volume":"12","author":"Chertow","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jnma.2025.08.110_bib0041","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchf.2023.06.036","article-title":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF: post-hoc analysis of EMPEROR-reduced [J]","volume":"12","author":"Dhingra","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.jnma.2025.08.110_bib0042","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits [J]","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.jnma.2025.08.110_bib0043","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-016-0789-4","article-title":"SGLT2 inhibitors: benefit\/risk balance [J]","volume":"16","author":"Scheen","year":"2016","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.jnma.2025.08.110_bib0044","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure [J]","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of the National Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968425003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968425003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:20:46Z","timestamp":1768483246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027968425003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0027968425003049"],"URL":"https:\/\/doi.org\/10.1016\/j.jnma.2025.08.110","relation":{},"ISSN":["0027-9684"],"issn-type":[{"value":"0027-9684","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of SGLT2 inhibitors on acute kidney injury in patients with chronic kidney disease, cardiovascular disease, and type 2 diabetes: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnma.2025.08.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Medical Association.","name":"copyright","label":"Copyright"}]}}